Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer.
Marisa L, Blum Y, Taieb J, Ayadi M, Pilati C, Le Malicot K, Lepage C, Salazar R, Aust D, Duval A, Blons H, Taly V, Gentien D, Rapinat A, Selves J, Mouillet-Richard S, Boige V, Emile JF, de Reyniès A, Laurent-Puig P. Marisa L, et al. Among authors: aust d. Clin Cancer Res. 2021 Sep 1;27(17):4768-4780. doi: 10.1158/1078-0432.CCR-21-0529. Epub 2021 Jun 24. Clin Cancer Res. 2021. PMID: 34168047 Free PMC article.
ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.
Laforest A, Aparicio T, Zaanan A, Silva FP, Didelot A, Desbeaux A, Le Corre D, Benhaim L, Pallier K, Aust D, Pistorius S, Blons H, Svrcek M, Laurent-Puig P. Laforest A, et al. Among authors: aust d. Eur J Cancer. 2014 Jul;50(10):1740-1746. doi: 10.1016/j.ejca.2014.04.007. Epub 2014 May 2. Eur J Cancer. 2014. PMID: 24797764
Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG.
Linge A, Löck S, Gudziol V, Nowak A, Lohaus F, von Neubeck C, Jütz M, Abdollahi A, Debus J, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Avlar M, Grosu AL, Bayer C, Belka C, Pigorsch S, Combs SE, Welz S, Zips D, Buchholz F, Aust DE, Baretton GB, Thames HD, Dubrovska A, Alsner J, Overgaard J, Baumann M, Krause M; DKTK-ROG. Linge A, et al. Among authors: aust de. Clin Cancer Res. 2016 Jun 1;22(11):2639-49. doi: 10.1158/1078-0432.CCR-15-1990. Epub 2016 Jan 11. Clin Cancer Res. 2016. PMID: 26755529
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).
Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L. Bonnetain F, et al. Among authors: aust d. Eur J Cancer. 2014 Nov;50(17):2983-93. doi: 10.1016/j.ejca.2014.07.011. Epub 2014 Sep 22. Eur J Cancer. 2014. PMID: 25256896 Review.
Overexpression of SIX1 is an independent prognostic marker in stage I-III colorectal cancer.
Kahlert C, Lerbs T, Pecqueux M, Herpel E, Hoffmeister M, Jansen L, Brenner H, Chang-Claude J, Bläker H, Kloor M, Roth W, Pilarsky C, Rahbari NN, Schölch S, Bork U, Reissfelder C, Weitz J, Aust D, Koch M. Kahlert C, et al. Among authors: aust d. Int J Cancer. 2015 Nov 1;137(9):2104-13. doi: 10.1002/ijc.29596. Epub 2015 May 21. Int J Cancer. 2015. PMID: 25951369 Free article.
229 results